Coronavirus: EMA launches accelerated review of a modified version of Pfizer vaccine

The European Medicines Agency (EMA) has declared the start of the procedure to review a modified version of Pfizer’s coronavirus vaccine as part of a better protection against specific variants of the virus, including Omicron.

“As the company progresses in the development of its adapted vaccine, the EMA will receive more data, including data on the immune response to the vaccine, as well as data on its efficacy against Omicron subvariants,” the EMA said in a statement.

“By launching an ongoing review, the EMA will be able to evaluate the data as soon as it becomes available,” the Amsterdam-based agency said, Le Figaro said.